23 July 2021 
EMA/CHMP/325680/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion 1 (post authorisation) 
Spikevax 
COVID-19 mRNA vaccine (nucleoside-modified) 
On 23 July 2021,  the Committee for Medicinal  Products for Human Use (CHMP)  adopted a positive opinion 
recommending a change to  the terms of the marketing authorisation for the medicinal product Spikevax. 
The marketing authorisation holder for this  medicinal product is Moderna Biotech Spain, S.L. 
The CHMP adopted an extension to the  existing indication as follows: 2 
“COVID-19 Vaccine Moderna is indicated for active immunisation to prevent COVID-19 caused by 
SARS-CoV-2 in individuals 18 12 years of age and older.” 
Detailed recommendations for the use of this  product will be described in the updated summary of 
product characteristics (SmPC), which will  be published in the  revised European public assessment report 
(EPAR), and will be available in all official European Union  languages after a decision on this change to 
the marketing authorisation has been granted by the  European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
